HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
BIOBOARD - EUROPE
Curetis obtains key patent for UnyveroTM technology
Curetis AG, a developer of next-level molecular diagnostic solutions, has been granted a core technology patent by IP Australia, the Australian patent office, for its UnyveroTM platform technology. The patent, "Reaction Vessel for PCR Device and Method of Performing PCR," is the first of several core technology patents filed by Curetis. Its claims cover PCR chamber vessels allowing the integrated amplification and detection of DNA sequences. Curetis has submitted patent applications covering this technology in other key regions, including Europe, the U.S. and Japan. The Company expects these additional patents to be granted in the near future.

The CE-marked UnyveroTM System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run.

"We are extremely pleased that the patent was granted without any restrictions in scope, as it covers a critical and indispensable aspect of our Unyvero platform," said Dr. Gerd Luedke, Director Bio-Assay Development of Curetis. "This decision supports all of our claims around a unique and proprietary way of combining end-point PCR with an array-based detection in a single reaction vessel - something that has never been done before. It affords Unyvero certain competitive advantages in terms of multiplexing capabilities and cost of goods at a very high number of analytes."

"Our Unyvero Solution offers a highly attractive alternative to real-time PCR because it integrates both amplification and detection," said Oliver Schacht, CEO of Curetis. "Unyvero allows for superior multiplexing as compared to conventional PCR devices and methods without increasing the risk of sample cross-contamination."

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy